Teleflex Beats Q2 Revenue, Lifts EPS Target, and Initiates $250M ASR

summarizeSummary

Teleflex exceeded Q2 revenue expectations, raised its adjusted EPS forecast, and unveiled a $250M accelerated buyback, though it lowered the revenue growth guide on slower interventional integration.

check_boxKey Events · Earnings and Guidance · TFX

• Q2 Revenue Beat, EPS In Line

  Revenue of $570.3M grew 28.9% YoY, beating the $559.6M consensus. Adjusted EPS of $1.76 edged past the prior year's $1.73.

• Raised Full-Year EPS Guidance

  Adjusted EPS guidance increased to $6.90–$7.20, up from prior outlook, driven by capital allocation actions including share repurchases and debt paydown.

• $250M Accelerated Share Repurchase

  Announced a $250M ASR to commence August 7, 2026, under the existing $1B buyback program, following $250M in open-market repurchases in Q2 at an average $130.85 per share.

• Revenue Growth Guidance Cut

  Reduced 2026 pro forma adjusted constant currency revenue growth guidance to 3.50%–4.50% from prior, citing slower-than-expected integration of the Biotronik Vascular Intervention business.

auto_awesomeAnalysis · TFX · Industrial Applications And Services

A strong second quarter saw revenue reach $570.3M, topping consensus, while management raised the full-year adjusted EPS guide to $6.90–$7.20. Confidence in the transformation is underscored by a new $250M accelerated share repurchase, layered on top of the $250M already bought back during Q2. The revenue growth outlook, however, was trimmed as the integration of the Biotronik Vascular Intervention business progressed more slowly than anticipated—a key area to monitor. Separately, FDA approval of EZPLAZ freeze-dried plasma opens a fresh growth channel.